key: cord-0768893-xlj2u89g
authors: Pinski, Amanda N.; Steffen, Tara L.; Zulu, Michael Z.; George, Sarah L.; Dickson, Alexandria; Tifrea, Delia; Maroney, Kevin J.; Tedeschi, Neil; Zhang, Yun; Scheuermann, Richard H.; Pinto, Amelia K.; Brien, James D.; Messaoudi, Ilhem
title: Corticosteroid treatment in COVID‐19 modulates host inflammatory responses and transcriptional signatures of immune dysregulation
date: 2021-11-03
journal: J Leukoc Biol
DOI: 10.1002/jlb.4cova0121-084rr
sha: 6b4f976535e4c8324b5dc8f0bced10e15a9c4a38
doc_id: 768893
cord_uid: xlj2u89g

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is the causative agent of coronavirus disease‐2019 (COVID‐19), a respiratory disease that varies in severity from mild to severe/fatal. Several risk factors for severe disease have been identified, notably age, male sex, and pre‐existing conditions such as diabetes, obesity, and hypertension. Several advancements in clinical care have been achieved over the past year, including the use of corticosteroids (e.g., corticosteroids) and other immune‐modulatory treatments that have now become standard of care for patients with acute severe COVID‐19. While the understanding of the mechanisms that underlie increased disease severity with age has improved over the past few months, it remains incomplete. Furthermore, the molecular impact of corticosteroid treatment on host response to acute SARS‐CoV‐2 infection has not been investigated. In this study, a cross‐sectional and longitudinal analysis of Ab, soluble immune mediators, and transcriptional responses in young (65 ≤ years) and aged (≥ 65 years) diabetic males with obesity hospitalized with acute severe COVID‐19 was conducted. Additionally, the transcriptional profiles in samples obtained before and after corticosteroids became standard of care were compared. The analysis indicates that severe COVID‐19 is characterized by robust Ab responses, heightened systemic inflammation, increased expression of genes related to inflammatory and pro‐apoptotic processes, and reduced expression of those important for adaptive immunity regardless of age. In contrast, COVID‐19 patients receiving steroids did not show high levels of systemic immune mediators and lacked transcriptional indicators of heightened inflammatory and apoptotic responses. Overall, these data suggest that inflammation and cell death are key drivers of severe COVID‐19 pathogenesis in the absence of corticosteroid therapy.

COVID-19 patients receiving steroids did not show high levels of systemic immune mediators and lacked transcriptional indicators of heightened inflammatory and apoptotic responses. Overall, these data suggest that inflammation and cell death are key drivers of severe COVID-19 pathogenesis in the absence of corticosteroid therapy.

antibodies, COVID19, comorbidity, corticosteroid, inflammation, male, SARS-CoV-2, transcriptional

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease-2019 (COVID- 19) , is responsible for millions of deaths globally. 1 Most infections result in asymptomatic or mild disease (∼80%). [2] [3] [4] However, advanced age (>65 years) and pre-existing comorbidities, such as obesity, diabetes, and pulmonary and cardio vascular disease, increase the probability of severe disease. 5, 6 Severe COVID-19 is characterized by pneumonia, lung fibrosis that often require ventilation, and a dysregulated inflammatory response that is followed by either recovery without complications, recovery with complications ("long COVID-19″), or fatality. 7, 8 Our understanding of COVID-19 disease progression is continuously evolving as more studies investigate longitudinal changes in immune responses during severe COVID-19. [9] [10] [11] Infection with SARS-CoV-2 results in the sequential induction of the innate and adaptive immune responses. 12 and 9. 14-17 Recognition by these PRRs leads to production of type I IFN and transcription of IFN stimulated genes (ISGs) that are important for establishing an antiviral state. Importantly, SARS-CoV-2 is known to antagonize the type I IFN response, leading to dysregulated and altered immune responses. 18, 19 Furthermore, a feature of severe COVID-19 has been shown to be NLRP3 inflammasome activation leading to translation of IL-1B, IL-18, and pyroptosis, all of which enhance the pro-inflammatory cytokine storm. 12, 20 During the initiation of the adaptive immune response, antigenspecific T and B cells are activated and recruited to the site of infection. 13, 21, 22 The spike and nucleocapsid protein are the dominant targets of the antibody (Ab) response, while the main target of neutralizing antibodies is believed to be the receptor binding domain (RBD) of the spike protein. 23, 24 In contrast, antigen-specific T cells detect a variety of SARS-CoV-2 structural and nonstructural proteins. [25] [26] [27] Multiple studies have performed correlative analyses that showed that severe disease is associated with heightened innate and dysregulated adaptive immune responses, however, the molecular signatures of these responses are unclear. 28 Several risk factors are associated with the development of severe COVID-19. 29 One of the most significant factors is age, with the overwhelming majority of hospitalizations and deaths occurring in individuals older than 65 years of age. [29] [30] [31] [32] Additionally, obesity, diabetes, hypertension, and the male sex have also been associated with increased susceptibility to severe COVID-19. [32] [33] [34] [35] Earlier studies suggest that increased basal levels of systemic inflammation ("inflammaging"), reduced frequencies of naïve T and B cells, and dysregulated adaptive immune responses may facilitate disease progression. [36] [37] [38] [39] For instance, a recent study found impaired cytotoxic CD8 T cell responses in aged, but not young patients, while others reported a positive correlation between age and inflammatory cytokines during acute COVID-19. 39, 40 However, the mechanisms underlying increased susceptibility to severe disease and dysregulated host responses to infection with age remain poorly defined.

In this study, we undertook a multiplatform approach to interrogate the host response in young (≤65 years) and aged (>65 years) males with severe COVID-19 who also suffered from comorbidities known to increase susceptibility to severe disease (e.g., diabetes, obesity, cardiovascular diseases) during the acute phase of COVID-19. Furthermore, we interrogated the impact of corticosteroid therapy, which has proven to be highly effective in suppressing the host inflammatory response. 41 Specifically, we characterized humoral, immune mediators, and transcriptional responses using whole blood samples collected 1-3 weeks post symptoms onset. Additionally, RNA sequencing data were leveraged to infer changes in circulating immune cell populations. Collectively, the data presented here show dampened inflammatory and apoptotic responses in young and aged corticosteroid-treated patients at the protein and transcriptional levels, suggesting that aberrant inflammation is a key driver of severe COVID-19.

Fifty-two blood samples were obtained from 41 male subjects categorized as "young" (≤65 years, n = 19) or "aged" (>65 years, n = 22) hospitalized with several COVID-19. Diabetes, obesity, and cardiovascular disease were the most common comorbidities amongst our study participants (Supplementary Table S1 ). Patients whose samples were obtained between January and February 2021 had received corticosteroids, which had become standard of care by then (Graphical Abstract; Supplementary Table S1 ). To perform a longitudinal analysis, samples were grouped into "young" and "aged" groups and categorized into 2 different time (T) periods based on days post symptom onset (DPSO): T1 encompasses 6-11 DPSO, while T2 includes 15-21 DPSO.

SARS-CoV-2-specific antibodies (Abs) and soluble mediators were quantified longitudinally in plasma using ELISA and Luminex assay respectively, while the focus reduction neutralization test (FRNT) was used to measure neutralizing Ab titers against SARS-CoV-2 (Graphical Abstract; Supplementary Fig. S1A ). Anti-RBD IgG were readily detected at T1 in both age groups, with the modest increase at T2 in young patients only ( Supplementary Fig. S1A ). Neutralizing Ab titers showed no differences between age groups or timepoints (Supplementary Fig. S1B ). Early in the pandemic, it has been reported that the bulk of the polyclonal neutralizing response targets the RBD region of SARS-CoV-2 spike protein and that RBD-specific Ab titers correlate with neutralization. 21, [42] [43] [44] [45] In line with these findings, we observed a positive correlation between anti-RBD IgG endpoint titers and SARS-CoV-2 neutralization (r = 0.3902, P = 0.008) ( Supplementary Fig. S1C ).

However, when we stratified patients by age, we observed a mod- We next measured levels of circulating immune mediators since severe COVID-19 is associated with a cytokine storm ( Supplementary   Fig. S1D and E). Additionally, patients were divided into two groups based on corticosteroid treatment (CORT) treatment or not (NC), and immune mediator levels were compared to those measured in agematched male healthy donors (HDs). Samples obtained before corticosteroid became standard of care exhibited significantly elevated levels of numerous cytokines, chemokines, and growth factors compared to HDs ( Supplementary Fig. S1D ). Levels of both pro-inflammatory (e.g., IL-1α/b, IL-6, IL-17a, IL-33) and anti-inflammatory (e.g., IL-13) cytokines were significantly increased in both age groups (Supplementary Fig. S1D ). Additionally, cytokines important for leukocyte proliferation and survival (e.g., IL-2, IL-3, IL-7, IL-12p70) were higher in both young and aged patients ( Supplementary Fig. S1D ). Markers of T cellmediated immunity including CD40L, granzyme B, and PDL1 were elevated in young and aged patients, with CD40L produced to a significantly greater level in young compared to aged patients. Although there was no significant increase in levels of interferon-α (IFNα) relative to HD, we observed enhanced levels of IFN-β and IFN-γ in both age groups ( Supplementary Fig. S1D ). Chemokines primarily involved in the recruitment of monocytes (e.g., fractalkine, G-CSF, MIP-1α) were elevated regardless of age, while MIP1b was exclusively elevated in aged patients. Mitogenic growth factors, such as PDGF-AA and VEGF, were notably elevated in all patients ( Supplementary Fig. S1D ). In contrast, fewer immune mediators were increased in CORT-treated young and aged patients ( Supplementary Fig. S1E ). We detected significantly higher concentrations of IL10, TNFα, IP10, RANTES, and EGF in both young and aged CORT-treated patients compared to HD (Supplementary Fig. S1E ). Two cytokines involved in anti-inflammatory and cellular cytotoxic responses, IL1RA and IL15 respectively, were significantly elevated in young CORT-treated patients only. On the other hand, levels of the chemokine, MIP1β were significantly higher in aged CORTtreated patients only ( Supplementary Fig. S1E ). Unlike NC patients, no significant changes in levels of IFN-γ and IFN-β were noted in CORTtreated young and aged patients.

We next investigated the host transcriptional response to severe COVID-19 in both age groups. Transcriptional profiles of the patients were compared to that of sex-and age-matched healthy donors (HD, NCBI BioProject PRJNA511612). Principal component analysis (PCA) showed a distinct separation between HD and COVID-19 patients, as well as between CORT and NC patients regardless of age, with no clear distinction between T1 and T2 ( Supplementary Fig. S2A ).

We first analyzed the transcriptional response in NC patients compared to age-matched HD ( Fig. 1; Supplementary Fig. S2) . Acute only DEGs detected in the aged patients enriched to GO terms associated with adaptive immunity (e.g., "B cell mediated immunity," "CD4 αβ T cell activation"). These DEGs encoded proteins with roles in T cell differentiation (e.g., IL4R, JAK3, RORA, ZBTB7B), activation (e.g., ARS, CD86), and regulation (e.g., FOXP1, TCIRG1), and were primarily upregulated relative to HD (Fig. 1D ).

Next, we carried out the same analysis for the larger cohort of CORT-treated patients to examine the effects of CORT on transcriptional changes (Supplementary Fig. 2 ; Supplementary Fig. S3 ).

Comparisons of each CORT-treated age group to age-matched HD identified nearly 1500 DEGs in each group ( Fig. 2A) . The majority of DEGs were upregulated in both young (84%) and aged (89%) patients with a significant overlap but were not differentially expressed To further investigate the impact of CORT treatment on COVID-19 progression at the molecular level, we compared the transcriptional profiles between CORT-treated and NC patients (Fig. 3 ). Significant overlap was detected between the transcriptional response to SARS-CoV-2 infection generated by untreated and CORT-treated patients within each age group ( Fig. 3A and B). DEGs unique to or shared between the treatment groups enriched to similar GO terms indicative of robust innate (e.g. "myeloid leukocyte activation/differentiation", "response to bacterium") and adaptive (e.g., "T cell differentiation") immunity ( Fig. 3C and D). For instance, in young patients (regardless of treatment) expression of genes important for T cell immunity such as CD28, and HLA-DMB were downregulated while that of B cell genes (e.g., IGHA1/2, IGHG1/2/3/4) and pro-apoptotic genes (e.g., BCL2A1, CD177) were upregulated (Fig. S4A) . In untreated young patients, other genes important for antiviral defense were downregulated (e.g., tory genes such as IL18RA and S100A9/P associated with neutrophilmediated immunity were uniquely upregulated in CORT-treated aged patients ( Supplementary Fig. S4B ). Genes encoding pro-inflammatory factors and ISGs, including BCL2L11, BIRC2, IFIH1, and IFNGR2, were exclusively expressed to high levels in only aged NC patients.

In order to identify clusters of genes that are similarly regulated overtime from T1 to T2 in both young and aged CORT-treated patients, we employed a two-way forward stepwise regression analysis (Fig. 4) .

This analysis was only carried out using samples from CORT-treated patients since we had a large number of samples in this category. Genes considered significant in a minimum of 16 comparisons were retained and clustered by temporal expression patterns, which resulted in two clusters (Fig. 4A) . The 768 genes in cluster 1 were downregulated at T1 and their expression remained reduced from T1 to T2, while genes in cluster 2 (n = 73) displayed the opposite pattern (Fig. 4A ).

Genes in cluster 1 enriched to several terms illustrating lymphocytemediated immunity (e.g., "lymphocyte differentiation," "TCR signaling") and response to signaling/stress (e.g., "response to peptide," "macroautophagy"; Fig. 4B ). Likewise, we detected several genes encoding subunits of the T cell receptor (e.g., TRAJ12, TRAC) as well as T cell coreceptors like CD28 and CD247 (Fig. 4C) . Several apoptosis mediators (e.g., TNFRSF10B) and genes regulating B cell immunity (e.g., MEF2C) also belonged to cluster 2. The few genes in cluster 2 included growth factor TGFB1, protease FURIN, and NFKB transcription factor component RELA, all of which were expressed to similar levels by young and aged patients at T1 and T2 (Fig. 4D ).

Next, we refined our longitudinal analysis by performing a regression against DPSO to identify longitudinally regulated genes (defined as protein-coding genes with FDR ≤ 0.05; Fig. 5 ). We first carried out this regression independently for each age group ( Fig. 5A and   B ). This analysis uncovered 108 genes in the CORT-treated aged group only. These genes were mostly downregulated overtime and enriched to GO terms related to classical complement (e.g., IGHV1-18, IGHV2-70), TLR signaling pathways (e.g., BIRC2, IRF4), as well as epigenetic modification and cell division (e.g., DNAJC6, ESCO1, H2AC12) ( Fig. 5A and B) . We then carried out these analyses using age as a co-variate. We identified 102 genes, 3 of which, DDX6

(viral RNA sensing), RAB2A (intracellular trafficking), and UBE2S (modulation of viral replication), showed opposite expression trends in the 2 age groups (Fig. 5C) . VAC14, which encodes a scaffold protein for intracellular vesicle transport, was downregulated in both young and aged patients over time, albeit to a greater magnitude in aged patients (Fig. 5C ).

HD. (B) Bubbleplot representing the functional enrichment of DEGs detected in young and aged patients identified in panel (A). The size of each circle represents the number of DEGs belonging to the indicated gene ontology (GO) term while color represents the FDR-corrected P-value (q-value). (C) Violin plots depicting normalized transcript counts of DEGs belonging to GO term "antigen processing and presentation" (young patients); grey color represents healthy donors (HD) while the blue color represents the non-CORT treated group (NC) (D) Violin plots depicting normalized transcript counts of DEGs belonging to GO terms "CD4 alpha-beta T cell activation" and "B cell-mediated immunity" (aged patients); grey color represents healthy donors (HD) while the blue color represents the non-CORT treated group (NC) 

Since these blood samples were obtained from a biobank premixed with an RNA stabilizer, immune phenotyping of circulating immune cells could not be performed in this study. Therefore, we applied deconvolutional analysis to our bulk RNA sequencing (RNA-seq) data to infer changes in cell frequencies (Supplementary Fig. S5 ).

To validate this approach, we obtained bulk RNA-seq and single-cell (sc)RNA-seq from a previously published study. 46 Fig. S5A ). [46] [47] [48] [49] We first compared cell frequencies among HD and CORT-treated patients. Although no significant differences were observed, there was a trend towards a decrease in CD4 memory cells and an increase in CD14 monocytes in severe COVID-19 patients irrespective of their age (Supplementary Fig. S5B and Table S3 ). No significant differences in the propor-tions of major immune cell types were detected between young and aged patients other than a modest decrease in CD8 naïve lymphocytes and CD16 + monocytes in aged patients ( Supplementary Fig. S5C and Table S4 ).

To further delineate differences in cell subsets between HD and COVID-19 patients at a higher resolution, we next performed Fig. S5D and E). No significant differences were observed for cell frequencies between T1 and T2.

Our current understanding of COVID-19 is rapidly evolving. However, immune mechanisms governing severe disease remain elusive but criti- and preliminary studies suggested beneficial effects of anti-TNF-α therapy. [58] [59] [60] Protection offered by peripheral Abs is still unclear, but a correlation between plasma and mucosal Abs suggests that protective Ab responses also be detected at the site of infection. 61 Consistent with previous studies, we detected a robust cytokine storm in severe COVID-19 patients that was significantly attenuated by corticosteroid treatment. 27, [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] In untreated patients, elevated levels of cytokines previously associated with severe COVID-19 were noted, including IL-1b, IL-6, IL-10, IL-12, IFN-γ, and TNF-α as previously reported. 40, [63] [64] [65] [66] [67] 69, 71, 75 Moreover, levels of TNF-α and MIP3β

were higher in aged patients relative to young patients, suggesting that some cytokines may serve as early, age-specific prognostic markers of severe disease. 76 Indeed G-CSF and GM-CSF, which were significantly increased in NC patients, were previously identified as hallmarks of severe COVID-19 in other studies. 66, 67, [77] [78] [79] In contrast, a were highly upregulated in both CORT-treated age groups. Severe COVID-19, as well as other severe viral respiratory infections, have been associated with NET formation, which may lead to enhanced inflammation, pulmonary dysfunction and changes in vasculature. [89] [90] [91] [92] [93] [94] Interestingly, we did not detect significant increases in systemic levels of IL-8, a neutrophil-specific chemoattractant and inducer of NET formation.

A deficient antiviral IFN response has been proposed as the mechanism behind severe COVID-19. 68, 83, 95, 96 Levels of type I (IFN-β) and

II (IFN-γ) IFN, but not IFN-α, were highly elevated in NC patients and accompanied by increases in cytokines that drive IFN production (e.g., IL-2, IL-12, and IL-13) and activation of IFN-secreting immune cells (e.g., IL-3, IL-7, IL-33). In contrast, levels of IFN-β and IFN-γ, were not significantly elevated compared to healthy donors in CORT-treated patients. However, the expression of IFN-stimulated genes (ISGs) was comparable between CORT-treated and untreated patients with only a few ISGs downregulated in untreated patients, such as STAT2 and STING1 recently implicated in RNA virus detection. 97 These data suggest that corticosteroid treatment can modulate type I IFN production, but not enough to disrupt ISG expression, which is likely initiated early in the infection (before CORT treatment). IFN production in NC patients could be mediated by peripheral plasmacytoid dendritic cells (pDCs; major producers of types I IFNs) and T cells (major producers of type II IFNs) as has been reported by other studies. 5, 27, 66, 74, 83, 96, [98] [99] [100] On the other hand, we detected robust changes in the expression of T cell activation genes in CORT-treated patients, suggesting dysregulation in cellular immunity and in line with our predicted T cell lymphopenia as reported by other studies. 5, 27, 66, 74, 83, 96, [98] [99] [100] We also detected lower expression of genes critical for T cellmediated immunity in NC patients including a number of MHC class I molecules (e.g., HLA-A) and T cell receptor signaling components (e.g., ZAP70). Additionally, we detected significantly elevated levels of soluble PDL1 in the plasma of NC patients, suggesting a dysregulation of adaptive immunity and potential exhaustion in these patients. The role of the antiviral response in the periphery is still unclear given that SARS-CoV-2 replication is restricted to the respiratory tract and that actively replicating virus has not been detected in the blood.

There are several limitations to our study. First, our study strictly examined severe COVID-19 in male individuals ages 46 to 76 with obesity and diabetes. Given the sex-specific differences in the immune responses to SARS-CoV-2 infection, we would therefore, caution against generalization of the data reported in this study. 101 Second, given our focus on only severe COVID-19 patients, we are unable to identify statistically significant biomarkers that differentiate mild, moderate, and severe COVID-19 cases from each other. Furthermore, we lack a comparison to COVID-19 patients without co-morbidities to uncover mechanisms driven by pre-existing medical conditions, although such a cohort is unlikely given that obesity, diabetes and hypertension are significant risk factors for severe COVID-19. 29, 102 Third, our findings specifically examine the peripheral blood response in severe COVID-19 rather than the site of infection: the respiratory tract. Also, our study does not profile post-acute phase of COVID-19

to understand short-and long-term outcomes (e.g., "long COVID19").

Future studies should aim to compare longitudinal respiratory and peripheral samples collected from larger cohorts of individuals with varying disease severity to identify and characterize tissue-specific transcriptional and functional changes. This will enable the identification of biomarkers of different disease severities. Our study also provide data to inform future clinical trials of COVID-19 therapeutics and advocates for the use of corticosteroids, such as dexamethasone. We observed that levels of IL6, a prognostic marker for the development of severe COVID-19 and fatality, were unchanged in CORT-treated, but not NC patients. 103 The long-term impact of CORT treatment on long-term immunity and vaccine responsiveness needs further investigation.

In summary, we performed a multi-platformed study incorporating both functional and transcriptional data to provide crucial insight into the molecular pathogenesis of severe COVID-19 in the peripheral blood of patients receiving and not receiving corticosteroids treatment. Our data support the hypothesis that severe COVID-19 is associated with pronounced dysregulation of all major immune cell subsets in blood, which confirms immunological misfiring in severe COVID-19.

However, profound changes are mediated by corticosteroid therapy.

The synergy of dysregulated innate and adaptive immunity fueled by an aberrant cytokine response may be key to driving systemic pathology in severe COVID-19.

Remnant IL1ra, IL1b, IL1a, IL2, IL3, IL33, IL4, IL5,   IL6, IL7, IL8, IL10, IL12p70, IL13, IL15, IL17A, IL17E, 

RNA was extracted from whole blood using the RiboPure™-Blood Kit (Life Technologies) per the manufacturer's instructions. Quality and quantity of RNA from whole blood was determined using an Agilent in either direction. To identify significant patterns of longitudinal gene expression, we applied a two-ways forward regression analysis using MaSigPro. 105 Only clusters containing genes that were considered statistically significant in at least 16 comparisons were retained. as the total number of normalized reads mapping to all viral genes.

Longitudinal analysis for CORT-treated young and age patients over T1 and T2 was performed with short time-series expression miner (STEM). 106 STEM specifically integrates a clustering algorithm based on the sole assumption that experiments can be naturally and sequentially ordered. This software further differentiates between random and chronological patterns. Identification of longitudinally regulated genes (LRGs) with age as a factor or by age cohort in CORT-treated patients was performed with DESeq2.

Functional enrichment of genes was performed with Metascape to identify significant Gene Ontology (GO) biological processes. 107 The Cytoscape network data integration and visualization tool was used to generate GO (biological process) term network. 108 Bar graphs, beanplots, bubbleplots, heatmaps, Venn diagrams and volcano plots were created in R. Graphs were generated with GraphPad Prism software (version 8).

Digital cell quantification (DCQ), (i.e., in silico flow cytometry) using gene expression data was carried out with ImmQuant using the IRIS database. Transcriptional data for age-and sexmatched healthy donors were retrieved from NBCI BioProject PRJNA511612.

In order to estimate the proportion of major cell subsets in blood samples, cell type-specific marker genes were identified using a reference scRNA-Seq dataset and used to deconvolute bulk RNAseq expression data. The scRNAseq data and cluster annotations were obtained from a recent study; bulk RNAseq data were generated in the present study. 46 Both the bulk and single cell count data were normalized using the vst function from the sctransform R package. 48 Cell type-specific markers for each scRNAseq cluster that were used for deconvolutional analysis were found using the NS-Forest machine learning method. 47 Marker gene by sample bulk and marker gene by cell single-cell matrices were used for deconvolution using the damped weighted least squares method. 49

Statistical significance between groups in panels 1A, 1B, 1D and 1E

were computed with Mann-Whitney U-test panels S5A and S5B with one-way ANOVA with Tukey's HSD. Spearman correlation was used to calculate correlations in panel 1C. *P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001.

The authors are grateful to all the study participants. 

The authors declare no competing interest.

The accession numbers for the RNA-Sequencing data reported in this paper is available in the NCBI BioProject PRJNA751085 .

COVID-19 as the leading cause of death in the United States

SARS-CoV-2 transmission from people without COVID-19 symptoms

Prevalence of SARS-CoV-2 antibodies in first responders and public safety personnel

The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Clinical determinants for fatality of 44,672 patients with COVID-19

Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm

Persistent symptoms in patients after acute COVID-19

Longitudinal analyses reveal immunological misfiring in severe COVID-19

Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans

Imbalanced host response to SARS-CoV-2 drives development of COVID-19

Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients

Adaptive immune responses to SARS-CoV-2 infection in severe versus mild individuals

Human coronaviruses: a review of virus-host interactions

Toll-like receptors and the control of immunity

MDA5 governs the innate immune response to SARS-CoV-2 in lung epithelial cells

SARS coronavirus and innate immunity

Activation and evasion of type I interferon responses by SARS-CoV-2

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling

Targeting the NLRP3 inflammasome in severe COVID-19

Functional SARS-CoV-2-specific immune memory persists after mild COVID-19

Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome

Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptorbinding domain by structure-guided high-resolution serology

The receptor binding domain of SARS-CoV-2 spike is the key target of neutralizing antibody in human polyclonal sera

Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome

SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease

The impact of pre-existing comorbidities and therapeutic interventions on COVID-19

Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications

The agerelated risk of severe outcomes due to COVID-19 infection: a rapid review, meta-analysis, and meta-regression

Correction to: incidence, clinical features, and outcomes of COVID-19 in Canada: impact of sex and age

Overweight, obesity, and risk of hospitalization for COVID-19: a community-based cohort study of adults in the United Kingdom

Obesity in patients with COVID-19: a systematic review and meta-analysis

Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health

Aging, immunity, and COVID-19: how age influences the host immune response to coronavirus infections?

Age-related dynamics of lung-resident memory CD8(+) T cells in the age of COVID-19

Why does COVID-19 disproportionately affect older people?

Impaired Cytotoxic CD8(+) T cell response in elderly COVID-19 patients

Age-severity matched cytokine profiling reveals specific signatures in Covid-19 patients

Therapeutic role of corticosteroids in COVID-19: a systematic review of registered clinical trials

Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients

Human neutralizing antibodies elicited by SARS-CoV-2 infection

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Longitudinal analyses reveal age-specific immune correlates of COVID-19 severity

A machine learning method for the discovery of minimum marker gene combinations for cell-type identification from single-cell RNA sequencing

Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression

Accurate estimation of cell-type composition from gene expression data

ImmQuant: a userfriendly tool for inferring immune cell-type composition from geneexpression data

xCell: digitally portraying the tissue cellular heterogeneity landscape

Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population

Serum IgA, IgM, and IgG responses in COVID-19

Cross-sectional evaluation of humoral responses against SARS-CoV-2 spike

Quick COVID-19 healers sustain anti-SARS-CoV-2 antibody production

Loss of Bcl-6-expressing T follicular helper cells and germinal centers in COVID-19

Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19

Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed

The potential for repurposing anti-TNF as a therapy for the treatment of COVID-19

Tumor necrosis factor inhibitors are associated with a decreased risk of COVID-19-associated hospitalization in patients with psoriasis-a populationbased cohort study

Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients

Imbalanced host response to SARS-CoV-2 drives development of COVID-19

Clinical and immunological features of severe and moderate coronavirus disease 2019

Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis

Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Factors of severity in patients with COVID-19: cytokine/chemokine concentrations, viral load, and antibody responses

Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

Cytokine release syndrome in COVID-19: innate immune, vascular, and platelet pathogenic factors differ in severity of disease and sex

Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China

Cytokine storm in COVID-19: the current evidence and treatment strategies

Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts

Clinical characteristics and immune injury mechanisms in 71 patients with COVID-19. mSphere

Higher level of neutrophilto-lymphocyte is associated with severe COVID-19

Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients

Serum cytokine and chemokine profile in relation to the severity of coronavirus disease 2019 in China

Temporal profiling of plasma cytokines, chemokines and growth factors from mild, severe and fatal COVID-19 patients

Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease

Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19

Transcriptional and proteomic insights into the host response in fatal COVID-19 cases

Corticosteroids in hospitalized patients with COVID-19

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Respiratory syncytial virus sequesters NF-kappa B Subunit p65 to Cytoplasmic inclusion bodies to inhibit innate immune signaling

NF-kappaB signaling differentially regulates influenza virus RNA synthesis

Identification of NF-kappaBdependent gene networks in respiratory syncytial virus-infected cells

Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3

Complex immune dysregulation in COVID-19 patients with severe respiratory failure

The emerging role of neutrophil extracellular traps in severe acute respiratory syndrome coronavirus 2 (COVID-19)

Neutrophil extracellular traps cause airway obstruction during respiratory syncytial virus disease

Neutrophil extracellular traps in immunity and disease

Excessive neutrophils and neutrophil extracellular traps in COVID-19

High level of neutrophil extracellular traps correlates with poor prognosis of severe influenza a infection

Neutrophil extracellular traps in COVID-19

Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison

Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans

SARS-CoV-2 induces doublestranded RNA-mediated innate immune responses in respiratory epithelial-derived cells and cardiomyocytes

Comprehensive mapping of immune perturbations associated with severe COVID-19

Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study

Longitudinal multi-omics analyses identify responses of megakaryocytes, erythroid cells, and plasmablasts as hallmarks of severe COVID-19

Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer

Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis

Interleukin-6 is a biomarker for the development of fatal severe acute respiratory syndrome coronavirus 2 pneumonia

systemPipeR: nGS workflow and report generation environment

maSigPro: a method to identify significantly differential expression profiles in time-course microarray experiments

STEM: a tool for the analysis of short time series gene expression data

Metascape provides a biologistoriented resource for the analysis of systems-level datasets

Cytoscape: a software environment for integrated models of biomolecular interaction networks